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Abstract
About 10% to 30% of patients with ataxia­telangiectasia (A­T) develop leukemias or lymphomas. There is considerable
interpatient variation in the age of onset and leukemia/lymphoma type. The incomplete penetrance and variable age of
onset may be attributable to several factors. These include competing mortality from other A­T­associated pathologies,
particularly neurodegeneration and interstitial lung disease, allele­specific effects of ataxia­telangiectasia mutated
(ATM) gene mutations. There is also limited evidence from clinical observations and studies using Atm knockout mice
that modifier genes may account for some variation in leukemia/lymphoma susceptibility. We have introgressed the
Atm  knockout allele (Atm ) onto several inbred murine strains and observed differences in thymic lymphoma
incidence and latency between Atm  mice on the different strain backgrounds and between their F1 hybrids. The
lymphomas that arose in these mice had a pattern of sequence gains and losses that were similar to those previously
described by others. These results provide further evidence for the existence of modifier genes controlling
lymphomagenesis in individuals carrying defective copies of Atm, at least in mice, the characterized Atm  congenic
strain set provides a resource with which to identify these genes. In addition, we found that fewer than expected Atm
pups were weaned on two strain backgrounds and that there was no correlation between body weight of young Atm­/­
mice and lymphoma incidence or latency.
Abbreviations:
A­T (ataxia­telangiectasia), ATM (ataxia­telangiectasia mutated), CGH (comparative genomic hybridization), GISTIC
(Genomic Identification of Significant Targets in Cancer), Gzm (granzyme), PBL (peripheral blood lymphocyte), Prkdc
(protein kinase), DNA­activated (catalytic polypeptide), Tcr (T cell receptor gene)
1This work was supported by National Institutes of Health grant R03 CA135528 (to M.M.W.) and the Ataxia­Telangiectasia
Children's Project (to M.M.W.). The authors disclose no potential conflicts of interest.
2This article refers to supplementary materials, which are designated by Tables W1 to W3 and Figures W1 and W2 and are
available online at www.neoplasia.com.
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Abstract
About 10% to 30% of patients with ataxia-telangiectasia (A-T) develop leukemias or lymphomas. There is con-
siderable interpatient variation in the age of onset and leukemia/lymphoma type. The incomplete penetrance
and variable age of onset may be attributable to several factors. These include competing mortality from other
A-T–associated pathologies, particularly neurodegeneration and interstitial lung disease, and allele-specific effects
of ataxia-telangiectasia mutated (ATM) gene mutations. There is also limited evidence from clinical observations
and studies using Atm knockout mice that modifier genes may account for some variation in leukemia/lymphoma
susceptibility. We have introgressed the Atmtm1Awb knockout allele (Atm−) onto several inbred murine strains and
observed differences in thymic lymphoma incidence and latency between Atm−/− mice on the different strain
backgrounds and between their F1 hybrids. The lymphomas that arose in these mice had a pattern of sequence
gains and losses that were similar to those previously described by others. These results provide further evidence
for the existence of modifier genes controlling lymphomagenesis in individuals carrying defective copies of Atm, at
least in mice, and the characterized Atm− congenic strain set provides a resource with which to identify these
genes. In addition, we found that fewer than expected Atm−/− pups were weaned on two strain backgrounds
and that there was no correlation between body weight of young Atm−/−mice and lymphoma incidence or latency.
Neoplasia (2014) 16, 129–136
Abbreviations: A-T, ataxia-telangiectasia; ATM, ataxia-telangiectasia mutated; CGH, comparative genomic hybridization; GISTIC, Genomic Identification of Significant
Targets in Cancer; Gzm, granzyme; PBL, peripheral blood lymphocyte; Prkdc, protein kinase, DNA-activated, catalytic polypeptide; Tcr, T cell receptor gene
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Introduction
Cancer follows respiratory injury as the major cause of mortality in
ataxia-telangiectasia (A-T), and 10% to 30% of patients with A-T
develop leukemias or lymphomas, generally of T cell origin. Non-
Hodgkin lymphoma is the most common malignancy, followed by
T cell acute lymphocytic leukemia [1]. T-prolymphocytic leukemia
has been reported in older patients. However, most patients with A-T
do not develop leukemia or lymphoma, and the age of onset varies for
those who do. The reason for this incomplete penetrance is unknown,
but there is some evidence that modifier genes may play a role. Con-
cordance between members of the same family for leukemia or lym-
phoma type and for the age of onset has been reported [2,3]. This
concordance could also be explained by differing phenotypic effects
of specific ataxia-telangiectasia mutated (ATM ) mutations, and in-
deed, missense mutations and small, in-frame deletions are found
in some concordant families. However, in other families with con-
cordant members, both ATM alleles are inactivated by truncating
mutations, and ATM protein is not detectable. In addition, a partic-
ular ATM mutation may cause leukemia or lymphoma in some
families yet lead to different leukemia/lymphoma types with different
ages of onset in other families.
Since the cloning of the gene defective in A-T, ATM, in 1995 [4],
at least five laboratories have created mice with Atm knockout alleles
[5–9]. Mice with a conditional Atm knockout allele [10] and at least
two Atm knock-in alleles have also been engineered [11,12]. Mice
homozygous for the Atm knockout alleles (referred to here as Atm−/−
mice) develop malignant thymic lymphomas resulting in diminished
life spans. On the basis of a literature survey, Reliene and Schiestl
[13] found that different laboratories report differing life spans for
Atm−/− mice. To explain the discrepancies, they focused on differences
in husbandry conditions (specific pathogen-free as opposed to con-
ventional facilities) and differences in commercial rodent chows. The
possibility that the strain background for the Atm knockout allele
may be a factor in varying life spans was also considered but somewhat
discounted because Atm−/− mice on the 129S6/SvEvTac background
survive for about the same time as Atm−/−mice on mixed backgrounds.
To determine if genetic background influences thymic lymphoma
susceptibility or latency in Atm−/− mice, we introgressed the Atmtm1Awb
knockout allele onto three additional inbred strain backgrounds. We
then monitored lymphoma development in the four different Atm−/−
inbred strains and in three Atm−/− F1 hybrid strains. Here, we report
strain-specific differences in lymphoma susceptibility and latency in
Atm−/− mice that suggest a role for modifier genes in these phenotypes.
In addition, we surveyed the lymphomas for recurrent sequence gains
and losses and for granzyme (Gzm) gene rearrangements. We found
sequence gains and losses that were largely in agreement with those
previously reported [14,15] and no evidence for previously reported
rearrangements of the GzmB and GzmC genes [16].
Materials and Methods
Generation of Atmtm1Awb Congenic Strains
129S6/SvEvTac Atmtm1Awb mice originally created by Barlow et al.
[5] served as the donor strain for the Atm knockout allele. The A/J
Atmtm1Awb and C57BL/6J Atmtm1Awb congenic strains were generated
by five marker-directed backcrosses using a chromosome elimination
“speed congenic” strategy we have previously described [17]. The
marker-directed backcrosses were followed by two conventional
backcrosses and five intercross generations. BALB/cByJ Atmtm1Awb
congenic mice were generated by 13 generations of conventional
backcrosses, followed by 5 intercross generations. These congenic
strains are available from the Jackson Laboratory (Bar Harbor,
ME). Atm−/− mice are infertile, so the congenic strains are main-
tained with Atm+/− breeders. For the remainder of this report, we will
refer to the background strains as 129S6, C57BL/6, BALB/c, and A/J.
F1 hybrids were generated by matings of 129S6 and C57BL/6 mice,
129S6 and A/J mice, and C57BL/6 and A/J mice. We will refer to
these hybrids as 129SB6F1, 129SAF1, and B6AF1 regardless of the
maternal and paternal strains used in the crosses.
Atm−/− and Atm+/+ mice used in this study were littermates gener-
ated from crosses of Atm+/− mice. The mice on all strain backgrounds
were bred contemporaneously and were weaned into common cages.
Consequently, mice of any given strain were housed in the same
cages as similarly aged mice of other strains.
Genotyping
Genotyping was performed on DNA isolated from tail snips and
amplified using Atm-F (5′-GACTTCTGTCAGATGTTGCTGCC-3′),
Atm-R (5′-CGAATTTGCAGGAGTTGCTGAG-3′), and Atm-Neo
(5′-GGGTGGGATTAGATAAATGCCTG-3′). This three-primer set
yields a 161-bp amplimer from the wild-type Atm allele and a 441-bp
amplimer from the knockout allele.
Histopathology
Tissues were fixed in 10% buffered formaldehyde for 48 to 72 hours,
followed by transfer into and storage in 70% ethanol until processed
and embedded in paraffin. Sections (6 μm) were stained with hema-
toxylin and eosin and examined on a Nikon Eclipse 51E microscope
(Nikon Instruments Inc, Melville, NY) equipped with a Nikon DS-
Fi1 camera with a DS-U2 unit and NIS-Elements F software.
Gzm Gene Rearrangement
Reverse transcription–polymerase chain reaction (PCR) was used
to detect fusion transcripts resulting from rearrangements of the
GzmB and GzmC genes. Approximately 2 μg of total RNA prepared
using an RNeasy Kit (Qiagen Sciences, Germantown, MD) was re-
verse transcribed (SuperScript II; Invitrogen, Grand Island, NY), and
the first strand cDNA was amplified using different primer pair com-
binations of GzmB forward primers (GzmB-F1 to GzmB-F7) and
GzmC reverse primers (GzmC-R1 to GzmC-R7, listed in Table W1).
To confirm the expression of GzmB and GzmC genes and the suit-
ability of the primers, primers of GzmB-F1 through GzmB-F7 were
used in PCR control reactions with GzmB-R1, and GzmC-R1 through
GzmC-R7 were assessed with GzmC-F1.
Array Comparative Genomic Hybridization
Genomic DNA was extracted from five tumors isolated from
129SAF1 mice and six tumors isolated from 129SB6F1 mice using
a DNeasy Blood and Tissue Kit (Qiagen Sciences) according to the
manufacturer’s instructions. DNA isolated from the tail of each re-
spective animal was used as reference DNA. DNA concentration and
sample buffer quality was determined using a NanoDrop spectro-
photometer (NanoDrop Technologies, Wilmington, DE). Samples
containing contaminants as indicated by low 260:230 ratios were
repurified using a DNA clean-up and concentrator kit (Zymo Research,
Irvine, CA). Labeling reactions were prepared using the Roche
NimbleGen Labeling Protocol (Roche NimbleGen, Madison, WI)
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for comparative genomic hybridization (aCGH; version 7.0) with 1 μg of
total DNA input. One microgram of test DNA and reference DNA was
labeled with Cyanine 5-Random Nonamers and Cyanine 3-Random
Nonamers, respectively, by Exo-Klenow fragment. Labeled DNA was
then purified by isopropanol precipitation, and the labeling efficiency
was determined using a NanoDrop spectrophotometer. Thirty-one
micrograms of the labeled DNA was prepared for hybridization,
placed on the mouse 720K whole-genome array, and hybridized at
42°C for ∼72 hours using a Maui Hybridization System (BioMicro
Systems, Salt Lake City, UT). The arrays were then scanned at
2 μM resolution on a NimbleGen MS 200 high-resolution scanner.
Data were processed through the NimbleScan 2.6 software package
(Roche NimbleGen) using the mouse 100718_MM9_WG_CGH
design files. Data were analyzed as cyanine 3 (Cy3) versus cyanine 5
(Cy5), and all samples passed quality control (QC) metrics cutoffs as
determined by Roche NimbleGen. Processed data were subsequently
loaded into Nexus Copy Number analysis software version 6 (Bio-
Discovery, El Segundo, CA) for Fast Adaptive States Segmentation
Technique segmentation analysis and copy number variation.
Analyses
GraphPad Prism software (GraphPad Software, Inc, La Jolla,
CA) was used for t tests, χ2 analyses to test for the expected ratio
of Atm−/− to Atm+/+ and Atm+/− pups, and Pearson correlation test-
ing of weight and lymphoma latency. Kaplan-Meier survival analyses
of overall survival and tumor-free survival were done using SigmaPlot
11.2 software (Systat Software Inc, San Jose, CA).
Results
In Utero and Neonatal Survival of Atm−/− Mice
Atm+/+ and Atm−/− mice were generated on all seven genetic back-
grounds by mating Atm+/− mice of the appropriate strains. We tested
whether the expected ratios of Atm wild-type (Atm+/+), heterozygous
(Atm+/−), and null (Atm−/−) pups were weaned and found fewer
Atm−/− pups than were expected on the C57BL/6 and A/J backgrounds
(χ2 = 8.567, P = .0138, df = 2, and χ2 = 31.152, P < .0001, df = 2,
respectively). We do not know whether the loss of these pups occurred
in utero or shortly after birth. There were also fewer BALB/c Atm−/−
weanlings than might be expected, but the difference was not quite
statistically significant (χ2 = 5.886, P = .0527, df = 2). The expected
numbers of Atm−/− pups were weaned on the 129S6, 129SB6F1,
129SAF1, and B6AF1 backgrounds. In addition, the expected ratio
of male to female Atm−/−mice was found for all the strain backgrounds
indicating that Atm loss does not lead to preferential in utero or neonatal
loss of one sex.
Interestingly, fewer A/J Atm+/− pups were weaned than expected
(χ2 = 6.682, P = .0097, df = 1) on the basis of the expected ratio
of 2:1 for Atm+/− to Atm+/+ pups. This raises the possibility that some
A/J Atm+/− mice were lost in utero or shortly after birth.
Atm−/− Mice Weigh Less than Atm+/+ Littermates
The mice were weighed weekly from 5 to 12 weeks of age
(Figure W1). On average, Atm−/− pups were smaller than Atm+/+
pups of the same age and sex throughout this period. At 5 weeks,
Atm−/− pups weighed, on average, 72% to 87% as much as Atm+/+
mice of the same sex and strain. As might be expected from the
dearth of A/J Atm−/− weanlings, these pups were smallest relative
to their Atm wild-type littermates.
Survival for Atm−/− Mice to 18 Months
We monitored 20 male and 20 female Atm−/− mice from each
strain and F1 hybrid for 18 months. The survival of Atm-null mice
depended on their strain background (Figure 1, A and B). Atm−/−
mice on the founder 129S6 background had a median survival time
of 113 days with only 1 of the 40 mice surviving to 18 months of
age. Mice on the BALB/c background had even shorter survival
times with a median survival of 74 days, and none of the mice on
this background lived longer than 109 days. Median survival was
longer for mice on the A/J and C57BL/6 backgrounds (385 and
353 days, respectively). Four of 40 A/J mice survived to 18 months.
Eight of 40 C57BL/6 mice survived to 18 months; 1 was killed at
383 days for brain tissue samples.
Atm−/− mice on 129SB6F1 and 129SAF1 hybrid backgrounds
survived longer (median survival of 200 days and 139 days, respec-
tively) than Atm-null mice on the 129S6 background but not as long
Figure 1. Overall survival of Atm−/− mice on four inbred strain
backgrounds (A) and three F1 hybrid backgrounds with the survival
of 129S6 Atm−/− mice for comparison (B).
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as on the A/J or C57BL/6 backgrounds. Atm−/− mice on the B6AF1
background had a median survival of 451 days, longer than that of
any of the other strain backgrounds tested. Five of 39 129SB6F1 mice
survived to 18 months. Four 129SAF1 mice survived to 18 months.
Six B6AF1 mice survived to 18 months.
Five Atm+/+ mice from each strain and sex were also followed for
survival to 18 months of age. As expected, most of these mice survived
the entire time, though in some strains, individual mice were lost.
However, there were two exceptions: all of the BALB/c male mice
died between 197 and 385 days of age, one from a thymic lymphoma;
and three A/J female mice became moribund between 405 and 497
days of age. These losses cannot be attributed to cage effects because
cage assignments at weaning were not based on strain or genotype.
Almost all of the Atm−/− mice on the BALB/c, 129S6, 129SB6F1,
and 129SAF1 backgrounds died of thymic lymphomas (Figure 2, A
and B). Thirty-nine of 40 BALB/c, 37 of 40 129S6, 26 of 39
129SB6F1, and 32 of 40 129SAF1 Atm−/− mice died of thymic lym-
phomas. C57BL/6 Atm−/− mice and B6AF1 Atm−/− mice were less
susceptible. Of the 40 C57BL/6 Atm nullizygous mice that became
moribund or reached 18 months of age, 21 had developed thymic lym-
phomas. In the B6AF1 hybrids, 5 of 20 males and 13 of 20 females
died of thymic lymphomas. However, Atm−/− mice on the A/J back-
ground appear to be resistant to thymic lymphomas. Only 3 of the
40 A/J Atm−/− mice that were followed until they became moribund
or reached 18 months of age developed thymic lymphomas. With
the exception of the B6AF1 hybrids, there were no significant dif-
ferences within the strains in lymphoma-free survival between males
and females, so the results for both sexes are combined in Figure 2.
Because few of the A/J Atm−/−mice died of thymic lymphomas but
nevertheless had a median survival shorter than C57BL/6 Atm−/−
mice, we considered the possibility that the deaths might be due to
other causes related to Atm loss. The necropsies we performed were
limited to detecting tumors, and no tumors were detected in 22 of the
40 A/J Atm−/− mice. The most frequently observed tumors in the
remaining mice were hepatocellular carcinoma (four tumors and
one tentative) and bronchioalveolar carcinoma (four tumors). Spon-
taneous bronchioalveolar carcinomas have been described in A/J mice,
and one was also observed in one of the A/J Atm+/+ controls. How-
ever, we are unaware of any reports that hepatocellular carcinomas are
common in A/J mice, and they were only observed in Atm−/− mice,
not the control mice. All the affected mice were male. In addition to
the three thymic lymphomas found in A/J Atm−/− mice, we observed
three lymphomas that were not classified as thymic lymphomas because
they contained no recognizable thymic structure.
Intriguingly, two of the A/J Atm−/− mice developed rhabdomyo-
sarcomas, a tumor type that has been associated with loss or muta-
tion of ATM in humans [18]. However, rhabdomyosarcoma was also
found in three of the control mice.
Decreased Body Weight Is Not Correlated with
Lymphoma Latency or Incidence
Atm−/− pups varied considerably in body size. For example, at 6 weeks
of age, female 129S6 Atm−/− mice weighed from 13 to 19.1 g. We
looked for a correlation between body weight at weekly intervals
between 5 and 12 weeks of age and the latency to lymphoma in 18male
and 18 female 129S6 Atm−/− mice that developed lymphoma. There
was no correlation for the female mice, but there was for male mice.
However, examination of a scatterplot of the data indicated that the
correlation was due to one mouse with exceptionally long survival
(Figure W2). When this outlier was excluded, there was no correlation
between weight and lymphoma latency. We also tested for an associa-
tion between weight and lymphoma incidence and weight and latency
in 20 male and 20 female C57BL/6 Atm−/− mice. On this strain back-
ground, 50% of the male mice and 55% of the female mice developed
thymic lymphomas by 18 months of age; the remainder died of other
causes or were killed at 18 months. Once again, there was no cor-
relation between body weight at 5 to 12 weeks of age and lymphoma
latency. At 5 weeks of age, female mice that went on to develop thymic
lymphomas had a mean body weight (± SEM) of 14.58 ± 0.20 g; those
that did not weighed 14.32 ± 0.32 g. For male mice that developed
or did not develop lymphoma, the mean body weights were 16.64 ±
0.36 g and 17.35 ± 0.35 g, respectively, at 5 weeks of age. These differ-
ences were not significant, nor were there any significant differences in
weight between affected and unaffected mice at weeks 6 through 12.
Figure 2. Lymphoma-free survival of Atm−/− mice on four inbred
strain backgrounds (A) and three F1 hybrid backgrounds with the
survival of 129S6 Atm−/− mice for comparison (B).
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Gzm Rearrangements and Genomic Copy Number Changes
Winrow previously reported GzmB-GzmC fusion transcripts in
lymphoma cell lines originating in Atm−/− mice [16]. We tested
RNA from 18 thymic lymphomas that arose in 129S6 Atm−/− mice
for the presence of these fusion transcripts by reverse transcription–
PCR using multiple primer sets. Though the primers we used read-
ily detected GzmB and GzmC transcripts, fusion transcripts were
not detected.
Genomic Gains and Losses
Figure 3A summarizes the aCGH profiles of sequence gains and
losses in the thymic lymphomas from each of five 129SAF1 Atm−/−
and six 129SB6F1 Atm−/− mice (summarized in Table W1). Most of
these copy number alterations are similar to those reported by Zha
et al. [15]. Ten of 11 lymphomas assayed had deletions of T cell
receptor gene β (Tcrβ; chromosome 6) with single-copy loss in seven
cases and loss of both copies in three others. All of the cases had
hemizygous deletions of distal chromosome 12 from about 109 Mb
to the termini; in individual tumors, these deletions extended proxi-
mally as far as 88 Mb. As noted by Zha et al., the deleted region
contains immunoglobulin heavy locus gene (Igh; 10 of 11 lymphomas),
B cell leukemia/lymphoma 11B (Bcl11b; 8 of 11 lymphomas), and T cell
lymphoma breakpoint 1 (Tcl1; 5 of 11 lymphomas). Six of 11 lympho-
mas had hemizygous deletions of Tcrγ on chromosome 13. Most of the
lymphomas had amplification of proximal chromosome 14 sequences
extending from 20 to 43 Mb to the Tcrα/δ locus. At, and distal to,
Tcrα/δ, the sequence copy number abruptly changed from gain to loss.
This region of loss also includes GzmB to GzmG. In three of the lym-
phomas, the deleted region extended to the end of the chromosome
(Figure 3B). Trisomy of chromosome 15 was noted by Liyanage et al.
[14] and Zha et al. [15]. The entirety of chromosome 15 was amplified
in 6 of 11 cases, whereas large regions of amplification were seen in 3 of
the remaining 5 cases. Four of 11 thymic lymphomas had single-copy
deletions within chromosome 19 containing 38 genes and microRNAs
(miRNAs), including phosphatase and tensin homolog (Pten; identified
as homozygously deleted by Zha), TNF receptor superfamily member 6
gene, and microRNA-107, which regulates cell cycle likely through
p53 activation.
There are some differences between our results and those of Zha
et al. [15]. Zha noted amplification of Notch1 (chromosome 2) in 5
of 18 cases; however, we only found one single-copy amplification of
the genomic region containing Notch1 in the 11 lymphomas we
assayed. We did not, however, screen for the activating Notch1
mutations found by Zha in a number of lymphomas that lacked
Notch1 amplification. Hemizygous loss of approximately 37 kb of
chromosome 3 sequence encompassing the neuroligin 1 gene (Nlgn1)
was detected in three lymphomas. Nlgn1 is expressed in a variety of
tissues, but the characterized role of its encoded protein is in the for-
mation of synaptic junctions, and its relevance to thymic lymphoma
is unknown.
Fourteen regions of recurrent sequence gain or loss were identified
by Genomic Identification of Significant Targets in Cancer (GISTIC)
analysis: loss of sequence on chromosomes 3, 6, 12, 13, 14, and 19
and gains of sequence on chromosomes 9, 14, and 15 (q-bound <
0.05, G-score > 1.0). See Figure 3C and Table W2 for specific re-
gions and associated genes and microRNAs. An arbitrary cutoff of
q-bound < 0.05 and G-score of 4.0 was used to highlight only those
regions more closely identified with the lymphoma phenotype. After
eliminating those regions that did not contain genes or miRNA, there
were 257 genes and miRNA associated with regions of copy number
gain, whereas there were 459 genes and miRNA associated with
regions of chromosomal loss.
Comparative analysis between lymphomas from the two hybrid
strains found only three regions overrepresented in a given strain.
Of those three regions, only one contained either a gene or miRNA,
that being the friend leukemia integration 1 (Fli1) region of chromo-
some 9 (P < .015). Fli1, a proto-oncogene originally identified as the
integration site of the Friend murine leukemia virus [19], is amplified
in a 70-kb region of chromosome 9 in the 129SA strain but not in the
129B6 strain. There are no nonsynonymous coding region differences
in Fli1 between A/J and C57BL/6J reported in dbSNP (build 128),
but the Fli1 transcript is known to be differentially expressed in hema-
topoietic stem cells between strains of the BXD recombinant inbred
strain set (Supplementary Table 2 of reference [20]).
Discussion
The identification of A-T modifier genes may lead to a better under-
standing of the molecular events that lead to leukemias and lym-
phomas in patients with A-T and may point to strategies to prevent
their occurrence. To detect the presence of modifier genes affecting
the incidence or latency of lymphoma in a murine model of A-T,
we followed mice homozygous for an Atm knockout allele on several
inbred strain and F1 hybrid backgrounds for the lymphoma devel-
opment. We observed strain differences in lymphoma latency and
incidence that we propose are due to modifier genes. There is some
evidence that changes in husbandry might affect lymphoma latency
in Atm−/− mice [13]. However, in the study reported here, all the
mice were housed in the same room and fed the same chow. In addi-
tion, the mice were not assigned to separate cages by strain back-
ground; mice of different strains were cohoused in the same cages.
Thus, the differences between strains in lymphoma latency and inci-
dence we observed are likely due to genetic background rather than
husbandry effects.
We found decreased lymphoma latency when the Atmtm1Awb
knockout allele was moved from the 129S6 background on which
it was originally generated to a BALB/c background. Protein kinase,
DNA-activated, catalytic polypeptide (Prkdc) is a candidate modifier
gene of the Atm-null allele in this strain. The BALB/c variant of
Prkdc, PrkdcBALB, is a hypomorphic allele that has been linked to
susceptibility to radiation-induced mammary tumors and thymic
lymphomas [21,22]. It is found in all BALB/c substrains but not
the other strains used in this study (data not shown). Prkdc encodes
DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a
protein involved in repair of DNA double-strand breaks and V(D)J
recombination. Scid mice have a truncating mutation in Prkdc that
leads to severe defects in both DNA double-strand break repair and
V(D)J recombination. Crosses between scid mice and Atm knockout
mice designed to generate offspring that are deficient in both Atm
and DNA-PKcs do not yield viable Atm−/− Prkdcscid/scid pups; the pups
die in utero [23,24]. In our study, it is possible that some Atm−/−
PrkdcBALB/BALB pups also died in utero, though the deficit of Atm−/−
pups was not statistically significant on this background.
A role for Prkdc as a potential modifier gene of lymphomagenesis
in Atm−/− mice is particularly interesting because some epidemi-
ological studies are beginning to suggest that PRKDC polymor-
phisms may be involved in human cancer. Auckley et al. [25]
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found lower DNA-PKcs activity in the peripheral blood lympho-
cytes (PBLs) of newly diagnosed patients with lung cancer than in
cancer-free controls. They also demonstrated a correlation between
DNA-PKcs activity in PBL and bronchial epithelial cells in the
same individuals, thus validating the use of DNA-PKcs activity
in PBL as a surrogate for activity in other tissue types. Someya
et al. [26] obtained similar results, finding low DNA-PKcs activity
in PBL collected from patients with breast and uterine cervix cancers
Figure 3. aCGH profiles of sequence gains and losses in thymic lymphomas from five 129SAF1 Atm−/− mice (designated by mouse
number and 129SA) and six 129SB6F1 Atm−/− mice (designated by mouse number and 129SB6) (A). The top panel represents the
frequency of gain or loss of the 21 chromosomal regions of mouse. The lower panel describes gain or loss for each sample by mouse
ID and strain. Most regions of gain or loss are single copy, whereas regions of gain or loss greater than 1 show a block of double the
height of the single-loss regions. (B) A representation of regions of sequence gain and loss specifically on chromosome 14 as per the
description in A. In addition, the gray regions were identified by GISTIC analysis as a highly overrepresented alteration associated with
this sample set. (C) Identification of highly overrepresented regions of copy number gain and loss by GISTIC analysis. Within the upper
panel are 14 regions where there is a statistically significant high frequency of aberrations over the background level in this sample set.
A q-bound of 0.05 and G-score of 1.0 was used. The G-score is a measure of frequency of occurrence and themagnitude of that occurrence.
The dark gray bar represents the peak region, maximal G-score, and nominal q-bound. The surrounding lighter gray shaded areas represent
boundaries generated by a leave-one-out recalculation of the peak region.
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before treatment. Both the Auckley and Someya studies are retro-
spective, raising the possibility that decreased DNA-PKcs activity
is a consequence of cancer rather than a contributor to carcinogen-
esis. However, a study by Bhatti et al. [27] found an associa-
tion between sequence polymorphisms in PRKDC and breast
cancer in radiologic technicians, and Danoy et al. [28] found a
potential association between a PRKDC sequence variant and head
and neck cancers in smokers. Of course, constitutional sequence
polymorphisms are not affected by cancer, but it is not known
if the variant sequences in either study have any effect on DNA-
PKcs activity.
Unlike BALB/c Atm−/− mice, C57BL/6 Atm−/− and A/J Atm−/−
mice had decreased lymphoma incidence and increased latency com-
pared to 129S6 Atm−/− mice. F1 hybrids between these various
strains had lymphoma latencies intermediate between those of the
parental strains. Reliene and Schiestl, referencing unpublished data,
noted a 50% survival at 12.5 months for Atm−/− mice on a C57BL/6
background [13]. This is consistent with our results. A/J Atm−/− mice
are resistant to thymic lymphoma development, but their overall sur-
vival is not significantly different from C57BL/6 Atm−/− mice. Thus,
some of the resistance in this strain may actually be attributable to
competing causes of mortality.
Regardless of strain background, Atm−/− mice were smaller and
shorter lived than their Atm+/+ littermates. Growth retardation is a
clinical feature of A-T [29] and has also been reported in Atm-
targeted knockout mice [5–7,9]. In this study, we found that lym-
phoma incidence or latency and decreased weight are dissociable
phenotypes. That is, within a strain, low weight is not predictive
of leukemia latency or incidence. We also noted fewer than expected
Atm−/− weanlings on the C57BL/6 and A/J backgrounds. Whereas
we are unaware of any evidence that A-T can cause fetal loss in
humans, it is difficult to determine the proportions of affected and
unaffected siblings in A-T families (discussed in reference [30]). The
mice in our study were genotyped at or shortly after weaning, so we
cannot distinguish if the losses occurred in utero or during the neo-
natal period. Because the loss only occurred in two strains, it may
result from background genetic effects intrinsic to the Atm−/− fetuses,
or it could indicate that C57BL/6 and A/J dams provide poor
maternal care to smaller or less healthy pups. Recently, Daniel et al.
[31] noted embryonic lethality in Atm−/− mice carrying transgenes
encoding kinase-dead Atm, and a similar observation was made by
Yamamoto et al. [12] in embryos homozygous for a knock-in allele
for kinase-dead Atm. The embryonic lethality did not occur with
Atm-null alleles.
Unlike Winrow [16], we did not detect GzmB-GzmC fusion tran-
scripts in any of the 18 lymphoma samples tested. There are several
possible reasons for the disparate findings. Our assay may fail to detect
fusion transcripts that are actually present in the lymphomas or the
fusion transcripts detected by Winrow might be an artifact of their
assay. It should be pointed out that Winrow’s results demonstrate
up-regulation of a sequence that hybridizes with cloned GzmC
cDNA, though the size of the transcript detected may be larger or
smaller than expect for a GzmB-GzmC fusion gene message. Our
samples consisted of primary lymphomas, whereas Winrow assayed
lymphoma cell lines, so it is also possible that the Gzm gene rearrange-
ments occur during acclamation to tissue culture.
In conclusion, our studies provide further evidence for the exis-
tence of modifier genes controlling lymphomagenesis in individuals
carrying defective copies of Atm. Furthermore, we have characterized
an Atm− congenic strain set that provides a resource with which to
identify these genes.
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Figure W1. Growth retardation in male (▪) and female (•) Atm−/− mice (dashed lines) compared with Atm+/+ littermates (solid lines).
Error bars indicate ±SD.
Figure W2. Scatterplot of lymphoma latency and weight at 6 weeks
of age for male 129S6 Atm−/− mice.
